Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace is in a potential buy range with its next earnings report scheduled for Apr. 26. The medical stock is about 3% above a 177.22 buy point from a second-stage.

Medpace Holdings Stock At The Top Of Buy Range With Earnings On Deck

Medpace is near a buy zone with earnings due on or around Apr. 26. The post Top-Rated Medpace Near Buy Zone With Earnings Due appeared first on Investor's Business Daily.

Top-Rated Medpace Near Buy Zone With Earnings Due

The stock of Medpace Holdings (NAS:MEDP, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.

Medpace Holdings Stock Appears To Be Significantly Overvalued

Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Medpace (MEDP): Can Its 3.5% Jump Turn into More Strength?

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2021 financial results after the market close on Monday, April 26, 2021. The Company will host a conference call the following morning, Tuesday, April 27, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 8676289. To access the conference call via w

Medpace Holdings, Inc. to Report First Quarter 2021 Financial Results on April 26, 2021

And a look at other questions investors might have.

A 4-Minute Look at Medpace Holdings

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2020 Results - Earnings Call Transcript

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Results Revenue for the three months ended December 31, 2020 increased 13.0% to $259.7 million, compared to $229.9 million for the comparable prior-year period. Revenue for the year ended December 31, 2020 increased 7.5% to $925.9 million, compared to $861.0 million for the year

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Results

Medpace Hldgs (NASDAQ:MEDP) releases its next round of earnings this Monday, February 15. Here is Benzinga's essential guide to Medpace Hldgs's Q4 earnings report.

A Preview Of Medpace Hldgs's Earnings

What do they know, and how? By a community of over 100,000 worldwide employee information gatherers reporting back to Market-Maker HQ trading desks. Based on traders' hedges of short positions required when filling “institutional” orders in big-volume block trades, they forecast their coming price range expectations.

Medpace Holdings: Best Medical Diagnostic Stock For Near-Term Price Gain, Say Market-Makers

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2020 financial results after the market close on Monday, February 15, 2021. The Company will host a conference call the following morning, Tuesday, February 16, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 9646903. To access th

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 15, 2021

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference: Credit Suisse Healthcare Conference Date: Tuesday, November 10, 2020 Presentation: 9:30 a.m. ET Speakers: August Troendle, President & Chief Executive Officer, Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations, and Kevin Brady, Executive Director of Finance A live webcast of the presentation will be

Medpace Holdings, Inc. to Present at the Credit Suisse Healthcare Conference

Medpace Holdings' (MEDP) CEO August Troendle on Q3 2020 Results - Earnings Call Transcript

Shares of Medpace Hldgs (NASDAQ:MEDP) moved lower by 1% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 53.52% year over year to $1.09, which beat the estimate of $1.07.

Recap: Medpace Hldgs Q3 Earnings

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Financial Results Revenue for the three months ended September 30, 2020 increased 6.5% to $230.4 million, compared to $216.2 million for the comparable prior-year period. On a constant currency organic basis, revenue for the third quarter of 2020 increased 5.8% compared to the third quarter of 2019. Backlog as of Sept

Medpace Holdings, Inc. Reports Third Quarter 2020 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2020 financial results after the market close on Monday, October 26, 2020.

Medpace Holdings, Inc. to Report Third Quarter 2020 Financial Results on October 26, 2020

Joint

LaZBoy

Novanta

Top Ranked Momentum Stocks to Buy for August 28th

Artisan Partners Asset Management

CoreLogic

FTI Consulting

Houghton Mifflin Harcourt

The service sector index read 58.1% in July, a 17-month high. Lest we forget, a reading above 48.5% indicates expansion of the broader economy.

Service Side of US Economy is Up and Running: 5 Top Picks

Descartes Systems Group

Lakeland Industries

Piedmont Office Realty Trust

West Pharmaceutical Services

Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently

Bet on These 5 Low Leverage Stocks This Earnings Season

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Medpace (MEDP) Is a Great Growth Stock

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2020 Results - Earnings Call Transcript

The clinical trial company's second-quarter financial results were better than expected.

Why Medpace Holdings Is Skyrocketing 13.5% Higher Today

Medpace Holdings stock soared Tuesday to a record high after the provider of clinical testing and research services for drugmakers late Monday forecast better-than-expected revenue for 2020.
The post Medpace Stock Soars To Record High On Improving Outlook appeared first on Investor's Business Daily.

Medpace Stock Soars To Record High On Improving Outlook

Medpace (MEDP) delivered earnings and revenue surprises of 61.90% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q2 Earnings and Revenues Top Estimates (Revised)

Medpace stock jumped in after-hours trading Monday, after rising in the regular session, as second-quarter revenue and full-year revenue guidance handily beat Wall Street expectations.

News for Medpace Holdings Stock (MEDP)